Welcome to our dedicated page for Annexon news (Ticker: ANNX), a resource for investors and traders seeking the latest updates and insights on Annexon stock.
Annexon, Inc. (NASDAQ: ANNX) is a clinical-stage biopharmaceutical company advancing therapies targeting C1q to address neuroinflammatory and autoimmune disorders. This page provides investors and researchers with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access real-time announcements about Annexon’s pipeline candidates including ANX005 for Guillain-Barré syndrome, ANX007 for geographic atrophy, and ANX1502 for systemic autoimmune conditions. Our curated news collection delivers verified press releases and analysis to support informed decision-making.
Key updates include clinical trial progress, scientific presentations, partnership announcements, and regulatory filings. All content is vetted for accuracy and relevance to complement inhibition therapies.
Bookmark this page for streamlined access to Annexon’s latest developments in targeting upstream complement pathways. Check regularly for authoritative updates on novel treatments for diseases with high unmet medical needs.
Annexon (Nasdaq: ANNX) announced positive final data from its Phase 2 clinical trial of ANX005 for Huntington’s disease (HD), showing complete C1q target inhibition and stabilization of disease progression over nine months. Of 28 participants, 23 completed the study, demonstrating sustained clinical benefits in patients with high baseline complement activity. The treatment was generally well-tolerated, with no serious adverse events reported. These results highlight ANX005’s potential as a novel therapy for HD, addressing a critical unmet need in the field.
Annexon (Nasdaq: ANNX), a clinical-stage biopharmaceutical company, announced that CEO Douglas Love will present at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 10:30 a.m. ET in New York City. The event is part of Annexon's effort to showcase its innovative complement medicines targeting autoimmune, neurodegenerative, and ophthalmic disorders. A live webcast will be available on the company's Investors page, with a 30-day replay option.
Annexon is developing a diverse pipeline aimed at treating classical complement-mediated diseases.
Annexon, Inc. (Nasdaq: ANNX) announced plans to present data from its complement-targeted pipeline at various medical meetings this summer. The company focuses on developing treatments for classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. Key presentations include topics related to lupus nephritis and warm autoimmune hemolytic anemia, scheduled for June 2022. Annexon's approach aims to inhibit C1q, offering potential protection against diseases impacted by the classical complement pathway, with clinical data expected throughout 2022 and 2023.
Annexon, a clinical-stage biopharmaceutical company, reported progress across its pipeline and first quarter 2022 financial results. With a broad portfolio of five candidates targeting complement-mediated disorders, Annexon anticipates eight clinical catalysts in 2022-2023. The lead candidate, ANX005, shows promise in treating Guillain-Barré Syndrome and Huntington's disease, demonstrating rapid clinical improvements. As of March 31, 2022, cash reserves totaled $206.7 million, sufficient to fund operations into 2024. However, the company reported a net loss of $35.4 million, reflecting increased expenses.
Annexon, Inc. (Nasdaq: ANNX) announced that CEO Douglas Love will participate in upcoming investor conferences: the BofA Securities 2022 Healthcare Conference on May 12, 2022, in Las Vegas, and the H.C. Wainwright Global Investment Conference on May 25, 2022, in Miami. The company specializes in developing complement-targeting medicines for autoimmune, neurodegenerative, and ophthalmic disorders. Webcasts of the events will be available on the company's website for 30 days post-conference. Annexon is advancing several clinical-stage candidates, including ANX005, ANX007, and ANX009.
Annexon completes enrollment in the Phase 2 ARCHER trial
Annexon (NASDAQ: ANNX) has successfully finished enrollment for its Phase 2 ARCHER trial, assessing ANX007 in patients with geographic atrophy (GA). Results on the primary endpoint are expected in the first half of 2023 after a 12-month treatment. GA affects approximately 1 million Americans, leading to potential blindness. The trial includes 270 patients and will examine both monthly and bi-monthly dosing. ANX007 previously showed promising results in a Phase 1b trial, demonstrating safety and full target engagement in the eye.
Annexon, Inc. (Nasdaq: ANNX) will have its president and CEO, Douglas Love, participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 3:45 p.m. ET. The event will be accessible via live webcast on the company's Investors page, with an archive available for 30 days post-event. Annexon focuses on developing unique complement medicines aimed at treating complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. Their pipeline includes three clinical-stage candidates and innovative early-stage programs.
Annexon, a clinical-stage biopharmaceutical company (Nasdaq: ANNX), announced it will present preclinical data at the American Academy of Neurology Annual meeting from April 2-7, 2022. This data highlights their innovative approach to inhibiting C1q in complement-mediated diseases, which includes conditions like Guillain-Barré Syndrome and Huntington’s disease. Notable presentations include the efficacy of their therapy ANX005. The company aims to advance its clinical programs, leveraging its proprietary platform aimed at combating various complement-mediated disorders.
Annexon announced encouraging interim data from its Phase 2 study of ANX005 for Huntington’s Disease, showing positive tolerance and engagement at the six-month mark. Financially, the company reported a net loss of $37.4 million for Q4 2021, totaling $130.3 million for the year. As of December 31, 2021, Annexon had $242.7 million in cash, expected to fund operations into Q1 2024. Key milestones include further data releases for ANX005 and ANX009 in 2022, indicating a robust pipeline aimed at addressing complement-mediated diseases.
Annexon, a clinical-stage biopharmaceutical company (Nasdaq: ANNX), announced that CEO Douglas Love will join the “Orphan CNS Panel” at the Cowen 42nd Annual Healthcare Conference on March 8, 2022, at 2:10 p.m. ET. The panel focuses on complement-mediated conditions affecting the CNS. A live webcast will be available on Annexon's Investors page and will remain archived for 30 days post-event. Annexon is pioneering complement-targeting medicines aimed at autoimmune and neurodegenerative disorders, with a pipeline that includes three clinical-stage drug candidates and various early-stage programs.
FAQ
What is the current stock price of Annexon (ANNX)?
What is the market cap of Annexon (ANNX)?
